Autoantibody signatures in prostate cancer.
By Xiaoju Wang, Jianjun Yu, A. Sreekumar, S. Varambally, Ronglai Shen, D. Giacherio, R. Mehra, J. Montie, K. Pienta, M. Sanda and 5 more. New England Journal of Medicine, 2005
611 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/42015c6d9dc1ab3d0ef9029bc306e3e2104ed132
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Guido Kroemer
- L. Zitvogel
- T. Gajewski
- Larry Norton
- K. Murphy
- A. Tesnière
- Eleftherios P. Diamandis
- L. Galluzzi
In Molecular Biology
- L. Zitvogel
- Guido Kroemer
- A. Tesnière
- Steven A. Carr
- Larry Norton
- T. Gajewski
- K. Murphy
- Michael A. Gillette
Citations in the corpus
- Protein biomarker discovery and validation: the long and uncertain path to clinical utility (2006, background): “A compelling exception to the limited utility of immunoaffinity methods for discovery is the emerging use of lysates of diseased tissue to capture circulating autoantibodies, with subsequent identification of the effective antigen”
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007, background): “once have used multiplex ELISAs that can detect several different proteins simultaneously.(216) Similar assays using phage displays or aptamers to detect multiple peptides have also been reported.”
- Mining the plasma proteome for cancer biomarkers (2008, methodology): “Phage display has also been used to find antigen candidate”
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells (2011, background): “Antibody responses in early stage prostate cancer have been reported to be detected before PSA becomes detectably elevated (Wang et al., 2005).”
- Strategies for discovering novel cancer biomarkers through utilization of emerging technologies (2008, background): “Wang and colleagues have published data suggesting that autoantibody signatures might improve the early detection of prostate cancer”
- Cancer despite immunosurveillance: immunoselection and immunosubversion (2006, background): “Nevertheless, tumour-specific antibody responses (also known as antibody signatures) can be used to detect cancers such as prostate cancer at early stage”